Northland Securities Trims BrainsWay (NASDAQ:BWAY) Target Price to $5.00

BrainsWay (NASDAQ:BWAYGet Rating) had its target price trimmed by Northland Securities from $15.00 to $5.00 in a research report released on Thursday morning, The Fly reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts also recently issued reports on BWAY. HC Wainwright increased their price target on shares of BrainsWay from $15.00 to $16.00 and gave the stock a buy rating in a research note on Monday, August 22nd. Raymond James decreased their price target on shares of BrainsWay from $10.00 to $8.00 and set an outperform rating for the company in a research note on Thursday, August 11th.

BrainsWay Trading Up 1.3 %

Shares of NASDAQ:BWAY opened at $2.03 on Thursday. BrainsWay has a 12 month low of $1.90 and a 12 month high of $9.18. The company has a market cap of $33.45 million, a price-to-earnings ratio of -6.33 and a beta of 1.42. The company has a 50-day moving average price of $3.49 and a 200-day moving average price of $4.85.

Institutional Investors Weigh In On BrainsWay

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cowen AND Company LLC grew its holdings in BrainsWay by 8.0% in the second quarter. Cowen AND Company LLC now owns 916,909 shares of the company’s stock worth $4,557,000 after purchasing an additional 67,700 shares during the period. Wasatch Advisors Inc. grew its holdings in shares of BrainsWay by 4.7% during the first quarter. Wasatch Advisors Inc. now owns 1,285,631 shares of the company’s stock valued at $11,198,000 after buying an additional 58,172 shares during the last quarter. State Street Corp grew its holdings in shares of BrainsWay by 3.7% during the first quarter. State Street Corp now owns 162,609 shares of the company’s stock valued at $1,416,000 after buying an additional 5,846 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of BrainsWay during the second quarter valued at approximately $73,000. Finally, Advisor Group Holdings Inc. grew its holdings in shares of BrainsWay by 130.5% during the first quarter. Advisor Group Holdings Inc. now owns 4,552 shares of the company’s stock valued at $40,000 after buying an additional 2,577 shares during the last quarter. Hedge funds and other institutional investors own 47.94% of the company’s stock.

About BrainsWay

(Get Rating)

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Further Reading

The Fly logo

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.